Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104) by Gajewski Thomas F, Salama April KS, Niedzwiecki Donna, Johnson Jeffrey, Linette Gerald, Bucher Cynthia, Blaskovich Michelle A, Sebti Said M, Haluska Frank

Get full text

PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma by Alejandro Avilés-Salas, Luis Cabrera-Miranda, Norma Hernández-Pedro, Diana Sofía Vargas-Lías, Suraj Samtani, Wendy Muñoz-Montaño, Daniel Motola-Kuba, Luis Corrales-Rodríguez, Claudio Martín, Andrés F. Cardona, Andrés F. Cardona, Andrés F. Cardona, Cittim B. Palomares-Palomares, Oscar Arrieta

Subjects: Get full text

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials by Mattia Rediti, Aranzazu Fernandez-Martinez, David Venet, Françoise Rothé, Katherine A. Hoadley, Joel S. Parker, Baljit Singh, Jordan D. Campbell, Karla V. Ballman, David W. Hillman, Eric P. Winer, Sarra El-Abed, Martine Piccart, Serena Di Cosimo, William Fraser Symmans, Ian E. Krop, Roberto Salgado, Sherene Loi, Lajos Pusztai, Charles M. Perou, Lisa A. Carey, Christos Sotiriou

“…Here, we investigate the complexity of B and T cell receptor (BCR and TCR) repertoires in the context of two phase III trials, NeoALTTO and CALGB 40601, evaluating neoadjuvant paclitaxel with trastuzumab and/or lapatinib in women with HER2-positive breast cancer. …”
Get full text

Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis by Pallawi Torka, Levi D. Pederson, Michael V. Knopp, David Poon, Jun Zhang, Brad S. Kahl, Howard R. Higley, Gary Kelloff, Jonathan W. Friedberg, Lawrence H. Schwartz, Wyndham H. Wilson, John P. Leonard, Nancy L. Bartlett, Heiko Schöder, Amy S. Ruppert

“…Abstract Background Quantitative methods of Fluorodeoxyglucose Positron Emission Tomography (FDG‐PET) interpretation, including the percent change in FDG uptake from baseline (ΔSUV), are under investigation in lymphoma to overcome challenges associated with visual scoring systems (VSS) such as the Deauville 5‐point scale (5‐PS). Methods In CALGB 50303, patients with DLBCL received frontline R‐CHOP or DA‐EPOCH‐R, and although there were no significant associations between interim PET responses assessed centrally after cycle 2 (iPET) using 5‐PS with progression‐free survival (PFS) or overall survival (OS), there were significant associations between central determinations of iPET ∆SUV with PFS/OS. …”
Get full text

Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. by Niedzwiecki, D, Bertagnolli, M, Warren, R, Compton, C, Kemeny, N, Benson, AB, Eckhardt, S, Alberts, S, Porjosh, G, Kerr, D, Fields, A, Rougier, P, Pipas, J, Schwartz, J, Atkins, J, O'Rourke, M, Perry, M, Goldberg, R, Mayer, R, Colacchio, T

Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance) by Lynn Symonds, Ming Yu, YuHong Zhang, Fang-Shu Ou, Tyler J. Zemla, Kelly Carter, Monica Bertagnolli, Federico Innocenti, Linda JW Bosch, Gerrit A Meijer, Beatriz Carvalho, William M. Grady, Stacey A. Cohen

Subjects: “…calgb 89803 (alliance)…”
Get full text

STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER by V. A. Gorbunova

“…A final analysis of this patient group in CALGB/SWOG 80 405 trial is pending. The RAS analysis is pivotal for choice of 1st line chemotherapy.…”
Get full text

Sub-Lobar Resection: The New Standard of Care for Early-Stage Lung Cancer by Benjamin E. Lee, Nasser Altorki

“…Two recent randomized studies, JCOG 0802 and CALGB 140503, are reviewed here in the context of LCSG 0821. …”
Get full text

q-Diffusion leverages the full dimensionality of gene coexpression in single-cell transcriptomics by Myrl G. Marmarelis, Russell Littman, Francesca Battaglin, Donna Niedzwiecki, Alan Venook, Jose-Luis Ambite, Aram Galstyan, Heinz-Josef Lenz, Greg Ver Steeg

“…In the first, q-diffusion helps gain statistical significance for differential effects on patient outcomes when analyzing the CALGB/SWOG 80405 randomized phase III clinical trial, suggesting precision guidance for the treatment of metastatic colorectal cancer. …”
Get full text

SOBREVIDA GLOBAL DE PACIENTES COM LEUCEMIA LINFOBLÁSTICA AGUDA ACOMPANHADOS NA UNIDADE DE HEMATOLOGIA DO HOSPITAL GERAL DE FORTALEZA by IL Pontes, MS Cidrão, JBSC Cidrão, FET Filho, FM Cunha, DS Oliveira, FAC Silva, KMC Albuquerque, LA Gurgel, RM Ribeiro

“…Os protocolos utilizados durante esse período de avaliação foram o HYPERCVAD, CALGB8811 e CALGB9511. Em pacientes com BCR-ABL1 positivo ou cariótipo com translocação 9;22 foi associado o inibidor de tirosina kinase. …”
Get full text

PERFIL EPIDEMIOLÓGICO DE PACIENTES COM LEUCEMIA LINFOBLÁSTICA AGUDA ACOMPANHADOS NA UNIDADE DE HEMATOLOGIA DO HOSPITAL GERAL DE FORTALEZA by IL Pontes, MS Cidrão, JBSC Cidrão, GM Oliveira, FM Cunha, DS Oliveira, FAC Silva, KMC Albuquerque, LA Gurgel, RM Ribeiro

“…Durante o período avaliado, a maioria dos pacientes com LLA T fez o esquema HYPERCAVD/HDMTX-ARAC; enquanto a maioria do grupo com LLA B fez o esquema CALGB 8811 ou CALGB 9511. Discussão: O tratamento da LLA é complexo e envolve esquemas de quimioterapia em vários ciclos diferentes, com momentos de intensificação na maioria dos protocolos atuais. …”
Get full text

Segmentectomy for patients with early-stage pure-solid non-small cell lung cancer by Atsushi Kamigaichi, Akira Hamada, Yasuhiro Tsutani

“…However, two recent pivotal clinical trials conducted by the Japanese Clinical Oncology Group/West Japan Oncology Group (JCOG0802/WJOG4607L) and the Cancer and Leukemia Group B (CALGB140503), which compared the survival outcomes between lobectomy and sublobar resection (the JCOG0802/WJOG4607L included only segmentectomy, not wedge resection), demonstrated the efficacy of sublobar resection in patients with early-stage peripheral lung cancer measuring ≤ 2 cm. …”
Get full text

Progress in radiotherapy for small‐cell lung cancer by Fujun Yang, Huan Zhao

“…A meta‐analysis demonstrated that thoracic radiotherapy (TRT) improves overall survival in SCLC. The results of the CALGB and CONVERT trials provide evidence for the efficacy of once‐daily high‐dose TRT. …”
Get full text

Lung Segmentectomy in NSCLC Surgery by Alberto Salvicchi, Simone Tombelli, Giovanni Mugnaini, Alessandro Gonfiotti

“…In 2023, the randomized phase III CALGB 140503 (Alliance) trial demonstrated the efficacy and non-inferiority of sublobar resection, including wedge resection, for clinical stage IA NSCLC with tumor diameter of < 2 cm. …”
Get full text

Unique amplification of BCR-ABL1 gene fusion in a case of T-cell acute lymphoblastic leukemia by Rima Koka, Najeebah A. Bade, Edward A. Sausville, Yi Ning, Ying Zou

“…It is significant that the patient responded to standard treatment with the CALGB 10403 protocol and supplementation with a tyrosine kinase inhibitor. …”
Get full text

Hepatic arterial chemotherapy for colorectal cancer liver metastases: a review of advances in 2003. by Chan, R, Kerr, D

“…RECENT FINDINGS: The large Medical Research Council (MRC)/European Organization for the Research and Treatment of Cancer (EORTC) and the smaller Cancer and Leukaemia Group B (CALGB) trials reported conflicting conclusions. Lack of difference in response rates and survival outcomes was noted by the European trial groups whereas the contrary was reported by the US investigators, with statistically significant difference in response rates of 48% and 25% and median survival of 22.7 months and 19.8 months, respectively, being observed, favoring HAC. …”

CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value by Yan Yang, Fang-Shu Ou, Emil Lou, Joanne Xiu, Hiroyuki Arai, Francesca Battaglin, Heinz-Josef Lenz, Richard M Goldberg, Anthony F Shields, Yasmine Baca, Philip A Philip, John L Marshall, W Michael Korn, Andreas Seeber, Natsuko Kawanishi, Jingyuan Wang, Shivani Soni, Wu Zhang, Shannon M Mumenthaler, Joshua Millstein, Priya Jayachandran, Federico Innocenti, Annika Lenz, Sandra Algaze, Taline Khoukaz, Evanthia Roussos Torres, Jim P Abraham, Benjamin A Weinberg, Alan P Venook

“…The impact on treatment outcomes was assessed in two cohorts, including 6341 real-world patients and 429 patients from the Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial.Results CCR5/CCL5 expression was higher in right-sided versus left-sided tumors, and positively associated with consensus molecular subtypes 1 and 4. …”
Get full text

A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studiesResearch in context by Benedetta Conte, Fara Brasó-Maristany, Adela Rodríguez Hernández, Tomás Pascual, Guillermo Villacampa, Francesco Schettini, Maria J. Vidal Losada, Elia Seguí, Laura Angelats, Isabel Garcia-Fructuoso, Raquel Gómez-Bravo, Natàlia Lorman-Carbó, Laia Paré, Mercedes Marín-Aguilera, Olga Martínez-Sáez, Barbara Adamo, Esther Sanfeliu, Beatrice Fratini, Claudette Falato, Núria Chic, Ana Vivancos, Patricia Villagrasa, Johan Staaf, Joel S. Parker, Charles M. Perou, Aleix Prat

“…Association of IGG with pathological complete response (pCR) was assessed in CALGB-40603 and BrighTNess. Immune significance of IGG was estimated through CIBERSORTx and EcoTyper. …”
Get full text

Vincristine-Induced Seizure from Drug Interactions: A Case Report and Review of Literature by Shima Heidari, Mahsa Panahishokouh, Davoud Babakhani, Sohrab Aghabeigi, Mohammad Vaezi, Shahideh Amini, Molouk Hadjibabaie, Bita Shahrami

“…We present a young man with a history of controlled childhood seizures who was diagnosed with pre-B-cell ALL and developed generalized tonic-clonic seizures following the Cancer and Leukemia Group B (CALGB) 8811 regimen. The patient also received oral itraconazole to prevent fungal infection initiated by chemotherapy. …”
Get full text

Diagnosis and treatment of diffuse large B-cell lymphoma by Ulrich J. M. Mey, Felicitas Hitz, Andreas Lohri, Stefanie Pederiva, Christian Taverna, Alexander Tzankov, Oliver Meier, Karen Yeow, Christoph Renner

“…aaIPI = age-adjusted International Prognostic Index; ABC = activated B-cell – like; ACVBP = doxorubicin, cyclophosphamide, vincristine, bleomycin and prednisone; ASCO = American Society of Clinical Oncology; BCCA = British Columbia Cancer Agency; CALGB = Cancer and Leukaemia Group B; CEPP = cyclophosphamide, etoposide, procarbazine and prednisone; CHOEP = cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone; CHOP = cyclophosphamide, doxorubicin, vincristine and prednisone; CNS = central nervous system; CORAL = Collaborative Trial in Relapsed Aggressive Lymphoma; CR = complete response; CT = computerised tomography; DFS = disease-free survival; DLBCL = diffuse large B-cell lymphoma; DSHNHL = German High-Grade Non-Hodgkin's Lymphoma Study Group; EFS = event-free survival; EORTC = European Organization for Research and Treatment of Cancer; ESHAP = etoposide, solumedrol, high-dose cytarabine and platinum; EPOCH = etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin; ESMO = European Society for Medical Oncology; FIL = Italian Lymphoma Foundation; FISH = fluorescence in-situ hybridisation; GCB = germinal centre B-cell – like; G-CSF = granulocyte colony-stimulating factor; GELA = Groupe d'Etude des Lymphomes de l'Adulte; HDT = high dose therapy; HIV = human immunodeficiency virus; ICE = ifosfamide, carboplatin and etoposide; IFRT = involved-field radiation therapy; IPI = International Prognostic Index; LDH = lactate dehydrogenase; MInT = MabThera International Trial; NCCN = National Comprehensive Cancer Network; NHL = Non-Hodgkin’s lymphoma; NOS = not otherwise specified; OS = overall survival; PET = positron emission tomography; PMBL = primary mediastinal B-cell lymphoma; PFS = progression-free survival; R = rituximab; RICOVER-60 = Rituximab with CHOP over age 60 years; SCT = stem cell transplantation; SAKK = Schweizerische Arbeitsgruppe für Klinische Krebsforschung; SWOG = Southwest Oncology Group; WHO = World Health Organisation. …”
Get full text